For Brain Health

We are developing diagnosis of prodromal dementia and therapeutics for Alzheimer’s Disease and dementia with Lewy bodies.

About Us

BRI Pharma evaluates risk of dementia with blood and supplies the preventive tools of dementia.


BRI Pharma develops disease-modifying drugs for AD and DLB.


BRI Pharma is engaged with health science companies and collaborates with CNS targeting companies.

R&D Portfolio

Novel drug candidates for AD and DLB and Diagnosis Technologies.

BRI-301: T-type calcium channel enhancer

BRI-101: FABP3 inhibitor

BRI-601: FABP7 inhibitor

B-refine: diagnostic system

Latest News